SciSparc Ltd.'s subsidiary NeuroThera Labs reported significant enrollment momentum for SCI-210, a cannabinoid-based treatment for autism spectrum disorder (ASD), with 26 of the planned 60 children enrolled in its double-blind trial at Soroka Medical Center. The company is also pursuing FDA Orphan Drug Designation for SCI-110, a drug candidate for adult Tourette syndrome, and has engaged RK Strategies to support this regulatory effort. SCI-110 is currently in Phase IIb trials across the US, Germany, and Israel, following Phase IIa results showing a 21% average tic reduction. SciSparc Ltd. operates in the pharmaceutical industry, developing cannabinoid-based therapeutics for central nervous system disorders.

SciSparc Ltd.'s subsidiary, NeuroThera Labs Inc., completed a C$5.4 million private placement financing on August 15, 2026. SciSparc invested C$2.7 million, subscribing for 22,500,000 units at C$0.12 per unit, each comprising one common share and one warrant exercisable at C$0.16 for three years. Following the transaction, SciSparc holds approximately 44.6% of NeuroThera’s outstanding shares, with its stake valued at roughly C$30 million. The proceeds will support general working capital and administrative expenses. SciSparc Ltd. operates in the pharmaceutical industry, focusing on clinical-stage cannabinoid-based drug development for central nervous system disorders.

SciSparc Ltd.'s subsidiary NeuroThera Labs initiated a Phase IIb clinical trial site at the Yale Child Study Center for SCI-110, a cannabinoid-based drug candidate targeting Tourette Syndrome in adults. The randomized, double-blind study builds on positive Phase IIa results showing a 21% average tic reduction and will evaluate efficacy and safety at sites in the U.S., Germany, and Israel. SciSparc Ltd. operates as a clinical-stage pharmaceutical company focused on developing cannabinoid-based therapeutics for central nervous system disorders.